Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury–Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant
Dandoy CE, Kim S, Chen M, Ahn KW, Ardura MI, Brown V, Chhabra S, Diaz MA, Dvorak C, Farhadfar N, Flagg A, Ganguly S, Hale GA, Hashmi SK, Hematti P, Martino R, Nishihori T, Nusrat R, Olsson RF, Rotz SJ, Sung AD, Perales MA, Lindemans CA, Komanduri KV, Riches ML. Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury–Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant. JAMA Network Open 2020, 3: e1918668. PMID: 31913492, PMCID: PMC6991246, DOI: 10.1001/jamanetworkopen.2019.18668.Peer-Reviewed Original ResearchConceptsHematopoietic stem cell transplantAllogeneic hematopoietic stem cell transplantMucosal barrier injury laboratoryMBI-LCBIOutcomes of patientsStem cell transplantBloodstream infectionsCumulative incidenceCell transplantRisk factorsDay 100First allogeneic hematopoietic stem cell transplantMarrow Transplant Research databaseHost disease (GVHD) prophylaxisLansky performance statusTransplant-related mortalityOne-year mortalityTranslocation of bacteriaCord blood graftsCause of deathChronic graftConsecutive pediatricHost diseaseMyeloablative conditioningAdult patients